Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290088 | 0.94 | MAPT (0.64) | MAPTVCAM1ALDH1A1LMNAMAPK1 | |
| SCHEMBL28853175 | 0.88 | MAPT (0.60) | MAPTVCAM1ALDH1A1LMNAMAPK1 | |
| SCHEMBL4949648 | 0.87 | MAPT (0.62) | MAPTVCAM1ALDH1A1LMNAMAPK1 | |
| SCHEMBL4983657 | 0.86 | KDM4E (0.66) | MAPTVCAM1ALDH1A1KMT2A | |
| SCHEMBL7206840 | 0.86 | MAPT (0.47) | MAPTVCAM1ALDH1A1LMNAMAPK1 | |
| SCHEMBL5458467 | 0.84 | VCAM1 (0.49) | MAPTVCAM1ALDH1A1LMNAMAPK1 | |
| SCHEMBL14453653 | 0.84 | KDM4E (0.56) | MAPTVCAM1ALDH1A1KMT2A | |
| SCHEMBL11450339 | 0.83 | VCAM1 (0.59) | VCAM1ALDH1A1HPGD | |
| SCHEMBL9277559 | 0.83 | MAPT (0.61) | MAPTALDH1A1LMNAMAPK1TLR4 | |
| SCHEMBL4257371 | 0.83 | MAPT (0.57) | MAPTALDH1A1LMNAMAPK1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0268849-B1 | Poly(aminoaromatic) compounds | DOW CHEMICAL CO (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5079275-A | Polyamino compound is an amino endcapped polyether, polyester, polycarbonate, resole, hydroxybutadiene | THE DOW CHEMICAL COMPANY (US) | 1992-01-07 | — | — | US | disclosed |
| US-4847416-A | Capping of polyols with aromatic amines | THE DOW CHEMICAL COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0268849-A2 | Poly(aminoaromatic) compounds | THE DOW CHEMICAL COMPANY (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | MAPT 39/4885VCAM1 830/4885ALDH1A1 3134/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | MAPT 35/4885VCAM1 811/4885ALDH1A1 3189/4885 |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | SLC18A3, TSPO, CHAT | MAPT 36/4885VCAM1 1459/4885ALDH1A1 2661/4885 |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SLC18A3, TSPO, CHAT | MAPT 36/4885VCAM1 1459/4885ALDH1A1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.